Abstract
Background
Previous observational studies have reported an association between Sjögren’s syndrome (SS) and an increased risk of Parkinson’s Disease (PD). However, the causal relationship between these conditions remains unclear. The objective of this study was to investigate the causal impact of SS on the risk of developing PD, utilizing the Mendelian randomization (MR) approach.
Methods
We conducted a bidirectional MR analysis using publicly available genome-wide association studies (GWAS) data. The primary analysis utilized the inverse-variance weighted (IVW) method. Complementary methods, such as MR-Egger regression, weighted mode, weighted median, and MR-pleiotropy residual sum and outlier (MR-PRESSO), were utilized to identify and correct for the presence of horizontal pleiotropy.
Results
The IVW MR analysis revealed no significant association between SS and PD (IVW: OR = 1.00, 95% CI = 0.94–1.07, P = 0.95). Likewise, the reverse MR analysis did not identify any significant causal relationship between PD and SS (IVW: OR = 0.98, 95% CI = 0.85–1.12, P = 0.73). The results from MR-Egger regression, weighted median, and weighted mode approaches were consistent with the IVW method. Sensitivity analyses suggested that horizontal pleiotropy is unlikely to introduce bias to the causal estimates.
Conclusion
This study does not provide evidence to support the assertion that SS has a conclusive impact on the risk of PD, which contradicts numerous existing observational reports. Further investigation is necessary to determine the possible mechanisms behind the associations observed in these observational studies.
Funder
National Natural Science Foundation of China
Guizhou Administration of Traditional Chinese Medicine
Publisher
Public Library of Science (PLoS)
Reference45 articles.
1. Updates in diagnostics, treatments, and correlations between oral and ocular manifestations of Sjogren’s syndrome;HS Choudhry;Ocul Surf,2022
2. Early diagnosis and treatment for Sjögren’s syndrome: current challenges, redefined disease stages and future prospects;B Wang;J Autoimmun,2021
3. Primary Sjögren’s syndrome: clinical phenotypes, outcome and the development of biomarkers;AV Goules;Immunol Res,2017
4. A comprehensive overview of living with Sjögren’s: results of a National Sjögren’s Foundation survey;SS McCoy;Clin Rheumatol,2022
5. The interplay between cognition, depression, anxiety, and sleep in primary Sjogren’s syndrome patients;R Goulabchand;Sci Rep-Uk,2022